Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors Octapharma
- 07 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 07 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 01 Nov 2016 Results assessing safety and tolerability using data from this and other three trials published in the International Journal of Clinical Pharmacology and Therapeutics.